Ozempic May Lower Breast Cancer Risk by 30%: The Latest Research
Recent observational research suggests that patients using glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), may experience a 30% lower incidence of breast cancer compared to those using other ... Read More